Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 296

1.

The Role of Maintenance Therapy in Patients With Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.

Rozental A, Gafter-Gvili A, Vidal L, Raanani P, Gurion R.

Hematol Oncol. 2018 Sep 14. doi: 10.1002/hon.2561. [Epub ahead of print]

PMID:
30216478
2.

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators.

N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104.

PMID:
30184451
3.

Five-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma.

Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, Schuster SJ, Rodriguez A, Hyman D, Calvo-Vidal MN, Smith SM, Svoboda J, Furman RR, Coleman M, Leonard JP.

Blood. 2018 Sep 4. pii: blood-2018-07-859769. doi: 10.1182/blood-2018-07-859769. [Epub ahead of print]

PMID:
30181173
4.

Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients.

Kumar A, Fraz MA, Usman M, Malik SU, Ijaz A, Durer C, Durer S, Tariq MJ, Khan AY, Qureshi A, Faridi W, Nasar A, Anwer F.

Curr Treat Options Oncol. 2018 Sep 1;19(10):50. doi: 10.1007/s11864-018-0565-6. Review.

PMID:
30173370
5.

Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.

Tilly H, Morschhauser F, Casasnovas O, Molina TJ, Feugier P, Gouill SL, Haioun C, Tournilhac O, Bouabdallah R, Gabarre J, Lamy T, Cabeçadas J, Becker S, Jardin F, Mounier N, Salles G; Lymphoma Study Association.

Lancet Haematol. 2018 Sep;5(9):e403-e410. doi: 10.1016/S2352-3026(18)30131-5.

PMID:
30172345
6.

An Attempt to Quantitate "Value" In Medical Oncologic Therapy.

Hancock C, Green L, Lestingi T, Bitran Md J.

Cureus. 2018 Jun 14;10(6):e2810. doi: 10.7759/cureus.2810.

7.

Feasibility and efficacy of addition of individualized dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.

Kater AP, van Oers MHJ, van Norden Y, van der Straten L, Driessen J, Posthuma WFM, Schipperus M, Chamuleau MED, Nijland M, Doorduijn JK, Van Gelder M, Hoogendoorn M, De Croon F, Wittebol S, Kerst JM, Marijt EWA, Raymakers RAP, Schaafsma MR, Dobber JA, Kersting SA, Levin MD; HOVON CLL study group.

Haematologica. 2018 Aug 16. pii: haematol.2018.193854. doi: 10.3324/haematol.2018.193854. [Epub ahead of print]

8.

An open-label, phase Ib study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.

Morschhauser F, Salles G, Le Gouill S, Tilly H, Thieblemont C, Bouabdallah K, Fabiani B, Ménard C, Tarte K, Cartron G, Houot R.

Blood. 2018 Aug 1. pii: blood-2018-05-853499. doi: 10.1182/blood-2018-05-853499. [Epub ahead of print]

PMID:
30068505
9.

Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.

Till BG.

Curr Treat Options Oncol. 2018 Jul 21;19(9):45. doi: 10.1007/s11864-018-0561-x. Review.

PMID:
30032463
10.

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance).

Byrd JC, Ruppert AS, Heerema NA, Halvorson AE, Hoke E, Smith MR, Godwin JE, Couban S, Fehniger TA, Thirman MJ, Tallman MS, Appelbaum FR, Stone RM, Robinson S, Chang JE, Mandrekar SJ, Larson RA.

Blood Adv. 2018 Jul 24;2(14):1705-1718. doi: 10.1182/bloodadvances.2017015396.

11.

Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.

Rubenstein JL, Geng H, Fraser EJ, Formaker P, Chen L, Sharma J, Killea P, Choi K, Ventura J, Kurhanewicz J, Lowell C, Hwang J, Treseler P, Sneed PK, Li J, Wang X, Chen N, Gangoiti J, Munster PN, Damato B.

Blood Adv. 2018 Jul 10;2(13):1595-1607. doi: 10.1182/bloodadvances.2017014845.

12.

Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Egle A, Steurer M, Melchardt T, Weiss L, Gassner FJ, Zaborsky N, Geisberger R, Catakovic K, Hartmann TN, Pleyer L, Voskova D, Thaler J, Lang A, Girschikofsky M, Petzer A, Greil R.

Ann Hematol. 2018 Jun 23. doi: 10.1007/s00277-018-3403-9. [Epub ahead of print]

PMID:
29934835
13.

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Egle A, Steurer M, Melchardt T, Weiss L, Gassner FJ, Zaborsky N, Geisberger R, Catakovic K, Hartmann TN, Pleyer L, Voskova D, Thaler J, Lang A, Girschikofsky M, Petzer A, Greil R.

Ann Hematol. 2018 Oct;97(10):1825-1839. doi: 10.1007/s00277-018-3380-z. Epub 2018 Jun 4. Erratum in: Ann Hematol. 2018 Jun 23;:.

14.
15.

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.

Eskelund CW, Albertsson-Lindblad A, Kolstad A, Laurell A, Räty R, Pedersen LB, Geisler CH, Jerkeman M, Grønbæk K.

Haematologica. 2018 May 24. pii: haematol.2018.194399. doi: 10.3324/haematol.2018.194399. [Epub ahead of print] No abstract available.

16.

Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study).

Stefoni V, Pellegrini C, Broccoli A, Baldini L, Tani M, Cencini E, Figuera A, Ansuinelli M, Bernocco E, Cantonetti M, Cox MC, Ballerini F, Rusconi C, Visco C, Arcaini L, Fama A, Marasca R, Volpetti S, Castellino A, Califano C, Cavaliere M, Gini G, Liberati AM, Musuraca G, Lucania A, Ricciuti G, Argnani L, Zinzani PL.

Oncologist. 2018 Sep;23(9):1033-1038. doi: 10.1634/theoncologist.2017-0597. Epub 2018 Apr 19.

PMID:
29674440
17.
18.

NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment.

Vo DN, Alexia C, Allende-Vega N, Morschhauser F, Houot R, Menard C, Tarte K, Cartron G, Villalba M.

Oncoimmunology. 2017 Dec 20;7(4):e1409322. doi: 10.1080/2162402X.2017.1409322. eCollection 2018.

PMID:
29632722
19.

Frontline treatment of diffuse large B-cell lymphoma in elderly: a systematic review of clinical trials in post-rituximab era.

Beygi S, Sadashiv S, Reilly JB, Khan C, Lister J.

Leuk Lymphoma. 2018 Apr 4:1-15. doi: 10.1080/10428194.2018.1443332. [Epub ahead of print]

PMID:
29616868
20.

A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.

Ujjani C, Wang H, Skarbnik A, Trivedi N, Ramzi P, Khan N, Cheson BD.

Blood Adv. 2018 Apr 10;2(7):762-768. doi: 10.1182/bloodadvances.2017015263.

Supplemental Content

Loading ...
Support Center